Peter Ho
Cho Ray Hospital(VN)Ludwig-Maximilians-Universität München(DE)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Chromatin Remodeling and Cancer, Cancer-related gene regulation, Epigenetics and DNA Methylation, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study(2018)601 cited
- → Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016(2004)253 cited
- → Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives(2003)227 cited
- → Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models(2017)165 cited
- → Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer(2008)119 cited
- → A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma(2011)